News & Events

News & Events

FeNO and CaNO in Respiratory Medicine: From a “Composite Signal” to “Compartment-Specific Inflammation”

 

Exhaled nitric oxide testing has become one of the most widely used non-invasive inflammatory biomarkers in respiratory medicine. In routine clinical practice, however, one fact is often oversimplified: what is commonly called “FeNO” is not a pure indicator that can be directly equated with “airway inflammation level.” With the maturation of the two-compartment model and multi-flow testing techniques, alveolar nitric oxide—CaNO—has gradually moved from being a “background value” of FeNO to a standalone parameter. The relationship between FeNO and CaNO is, in essence, the relationship between a “composite signal” and “compartment-specific information.”

Biological Origin: FeNO Is the “Result,” CaNO Is a “Component”

From a mechanistic perspective, FeNO and CaNO are not parallel entities. In the two-compartment model, exhaled nitric oxide is decomposed into two sources: CawNO, produced by inflamed tissue in the large airways, and CaNO, produced in the alveolar/peripheral small airway region. The FeNO value is determined by three factors: the baseline concentration of CaNO, the flux of CawNO diffusing across the airway wall into the airstream (JawNO), and exhaled flow rate. Simply put, FeNO is a “downstream reading,” whereas CaNO is one of the “upstream components” constituting that reading.

This distinction has direct clinical implications. An elevated FeNO may arise from central airway inflammation, from alveolar-region inflammation, or simply from a low exhaled flow rate causing a passive elevation. The value of CaNO lies precisely in separating the alveolar/small airway contribution from the composite signal, providing distal airway information that FeNO alone cannot deliver.

Normal Values and Measurement: FeNO Is “Readily Obtainable,” CaNO Is “Calculated”

The difference in acquisition is equally notable. FeNO is usually measured at a single flow rate of 50 mL/s, with a high degree of standardization, and the online testing procedure recommended by ATS/ERS has been widely implemented in clinical practice. The reference value for FeNO₅₀ in healthy adults is generally set at <25 ppb, and in children at <20 ppb.

CaNO cannot be obtained directly from any single exhaled flow rate. It requires measurement of eNO at at least two, and usually three, different exhaled flow rates, followed by indirect calculation using the two-compartment model equation; some simplified protocols use two-point correction at 50 mL/s and 200 mL/s. The reference value for CaNO in healthy adults is generally set at <5 ppb, and in children at <3 ppb. This difference in complexity directly affects accessibility: FeNO is suitable as a first-line screening and follow-up tool, whereas CaNO is more appropriate as a supplementary parameter when precise localization of inflammation is needed.

Clinical Focus: FeNO Anchors Type 2 Inflammation; CaNO Fills the Small Airway and Alveolar Gap

FeNO has the most mature evidence base, with its core role as a non-invasive marker of type 2 airway inflammation. In asthma, FeNO ≥25 ppb in adults or ≥35 ppb in children supports the presence of eosinophilic airway inflammation and is associated with responsiveness to inhaled corticosteroids and with the selection of biologics such as anti-IL-4Rα and anti-IL-5 agents. The limitations of FeNO are equally clear: atopic constitution, allergic rhinitis, and eczema can elevate FeNO without asthma; ICS or systemic corticosteroids suppress FeNO and may mask true type 2 inflammation. In addition, in patients with a heavy airway mucus burden, a thickened diffusion barrier can reduce DawNO and lower the FeNO reading; in such cases, a “normal” FeNO does not necessarily mean that inflammation is controlled.

Although the clinical evidence for CaNO is less extensive than that for FeNO, it targets an anatomical region that is a blind spot for FeNO. FeNO₅₀ mainly reflects inflammation in the central airways, whereas FeNO₂₀₀ and CaNO mainly reflect small airway inflammation. In interstitial lung disease, CaNO rises in the fibrotic stage due to iNOS activation and has been explored as an auxiliary diagnostic, severity-assessment, and subtype-differentiation marker. In COPD, CaNO can detect distal small airway lesions not covered by FeNO and is not markedly affected by smoking behavior, showing potential value in distinguishing asthma from asthma-COPD overlap. In studies of post-COVID sequelae, elevated CaNO has also been interpreted as a signal of persistent inflammation at the alveolar and bronchiolar level or mild alveolar-capillary membrane impairment.

Diagnostic Performance and Combined Testing: Complementary Rather Than Replaceable

When the two are compared directly for asthma diagnosis, FeNO generally outperforms CaNO. One study reported an AUC of approximately 0.896 for FeNO and approximately 0.649 for CaNO in diagnosing asthma. However, among asthma patients with a negative bronchodilator test, FeNO showed high sensitivity (about 95%) but limited specificity (about 65%), whereas CaNO showed the opposite tendency—sensitivity of about 55% and specificity of about 76%. This “high-low” performance profile precisely indicates that the relationship between the two is not replacement but complementarity.

Evidence for combined testing is accumulating across multiple disease areas. In bronchodilator-negative asthma, the combination of FeNO, CaNO, and small airway function indices increased diagnostic specificity to 92.5%, with an AUC of 0.857. In acute exacerbations of COPD, the diagnostic performance of FeNO₅₀ combined with CaNO in predicting lung function improvement after corticosteroid therapy was significantly higher than that of either test alone, and the correlation between CaNO and blood eosinophils was weak, suggesting that CaNO carries independent information beyond FeNO and blood eosinophils. The underlying logic is consistent with the two-compartment model: FeNO reflects the “total amount,” whereas CaNO reflects the “distal component.” A normal total does not necessarily mean a normal distal component, and an elevated total does not necessarily mean that inflammation is located at the same anatomical level.

Unresolved Issues and a Reasonable Positioning

Several practical constraints still hinder the clinical dissemination of CaNO. First, population coverage of normal reference intervals is insufficient; current ATS/ERS-related thresholds are derived mainly from adult White populations and children aged 6–12 years, and stratified data for older adults and different ethnic groups are limited. Second, standardization of calculation methods has not been unified; different flow combinations and model assumptions may yield inconsistent CaNO estimates, and cross-device and cross-center comparability still requires prospective validation. Third, CaNO is more complex to perform, and its feasibility in primary care and high-throughput outpatient settings is clearly lower than that of FeNO.

Based on current evidence, a pragmatic positioning is as follows: FeNO serves as the “first window” for type 2 airway inflammation, used for asthma identification, prediction of ICS responsiveness, and biologic stratification; CaNO provides supplementary compartment-specific information when FeNO cannot explain the clinical picture—for example, when FeNO is normal but the patient still has evidence of small airway dysfunction, when interstitial/alveolar involvement is suspected, or when asthma and ACO need to be distinguished. The 2025 Chinese expert consensus has explicitly incorporated FeNO₅₀, FeNO₂₀₀, CaNO, and FnNO into a multidimensional testing framework. Its aim is not to replace FeNO with CaNO, but to move exhaled nitric oxide testing from a single reading toward a localizable inflammation map based on the “upper airway—large airway—small airway/alveolar” compartmental logic.

References

  1. Zhang Mingyue, Hou Yan. Research progress of exhaled and alveolar nitric oxide in interstitial lung disease. Chinese General Practice, 2026, 29(18): 2571-2576.

  2. Qu Y, Li L, Guo J, et al. Chinese Expert Consensus on the Testing Process, Quality Control and Clinical Application of Fractional Exhaled Nitric Oxide (2025). The Clinical Respiratory Journal.

  3. Clinical Utility of Central and Peripheral Airway Nitric Oxide in Children with Different Types of Allergic Asthma. Journal of Asthma and Allergy. 2025.

  4. Expert Consensus on the Testing Process and Clinical Application of Fractional Exhaled Nitric Oxide (2025 Edition). Pulmonary Function Group, Respiratory Branch, Chinese Medical Association.

  5. Wei Zhen, Luo Shengfa, Deng Tingjun. Application value of combined FeNO₅₀ + CaNO testing in corticosteroid therapy for acute exacerbation of COPD. Contemporary Clinical Medicine, 2026, 38(1): 61-63.

  6. Clinical diagnostic value of FeNO, CaNO, and small airway function testing in bronchodilator-negative asthma. Medical Journal of Wuhan University, 2025, 46(11): 1455-1462.

  7. Research progress on the application of exhaled nitric oxide and alveolar nitric oxide in chronic obstructive pulmonary disease. Chinese General Practice, 2024.

  8. Progress in the application of alveolar exhaled nitric oxide in pediatric lung diseases. International Journal of Pediatrics, 2024.

  9. Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study.

  10. Fractional exhaled nitric oxide testing: normal reference values and clinical considerations. Health Education Material, Xiaogan First People’s Hospital, 2024.

 
 
Global cooperation

Advancing Precision in Respiratory Care

Please complete the form to contact our team